Free Trial
NASDAQ:LGVN

Longeveron Q2 2025 Earnings Report

Longeveron logo
$0.68 -0.59 (-46.62%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.68 0.00 (-0.28%)
As of 08/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Longeveron EPS Results

Actual EPS
N/A
Consensus EPS
-$0.35
Beat/Miss
N/A
One Year Ago EPS
N/A

Longeveron Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.41 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Longeveron Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Longeveron Earnings Headlines

Longeveron Announces Up To $17.5 Million Public Offering
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
See More Longeveron Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Longeveron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longeveron and other key companies, straight to your email.

About Longeveron

Longeveron (NASDAQ:LGVN), a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

View Longeveron Profile

More Earnings Resources from MarketBeat